Alector Company
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Investors
Total Funding:
194500000
Headquarters:
San Francisco, California, United States
Funding Status:
IPO
Employee Number:
101-250
Estimated Revenue:
$10M to $50M
Last Funding Type:
Series E
Number Of Exists:
101-250
Last Funding Date:
2018-07-25
Investors Number:
20
Founded Date:
2013-01-01
Industry:
Neurodegeneration and aging